Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacovigilance01:19

Pharmacovigilance

2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Drug Regulation01:25

Drug Regulation

3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

423
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Single National Formulary: solution or distraction?

Drug and therapeutics bulletin·2026
Same journal

Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults.

Drug and therapeutics bulletin·2026
Same journal

Lipid-lowering for people with chronic kidney disease: a narrative review.

Drug and therapeutics bulletin·2026
Same journal

Study confirms benefits of continuous glucose monitoring in type 2 diabetes.

Drug and therapeutics bulletin·2026
Same journal

Update on spasticity: part-2 - physical, pharmacological and surgical management.

Drug and therapeutics bulletin·2026
Same journal

Reducing thrombosis risk much earlier in pregnancy: the new NHS Maternal Care Bundle.

Drug and therapeutics bulletin·2026

Related Experiment Video

Updated: May 1, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Statin labelling may overstate adverse events

    Drug and Therapeutics Bulletin
    |April 29, 2026
    PubMed
    Summary
    This summary is machine-generated.

    Statin therapy product labels accurately reflect adverse effects identified in clinical trials. This meta-analysis confirms that reported side effects align with evidence from randomized controlled trials.

    Keywords:
    Drug-Related Side Effects and Adverse ReactionsHealth Care Quality, Access, and Evaluation

    More Related Videos

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    13.2K
    Covalent Labeling with Diethylpyrocarbonate for Studying Protein Higher-Order Structure by Mass Spectrometry
    10:36

    Covalent Labeling with Diethylpyrocarbonate for Studying Protein Higher-Order Structure by Mass Spectrometry

    Published on: June 15, 2021

    5.1K

    Related Experiment Videos

    Last Updated: May 1, 2026

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    14.8K
    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    13.2K
    Covalent Labeling with Diethylpyrocarbonate for Studying Protein Higher-Order Structure by Mass Spectrometry
    10:36

    Covalent Labeling with Diethylpyrocarbonate for Studying Protein Higher-Order Structure by Mass Spectrometry

    Published on: June 15, 2021

    5.1K

    Area of Science:

    • Cardiovascular Medicine
    • Clinical Pharmacology
    • Evidence-Based Medicine

    Background:

    • Statins are widely prescribed lipid-lowering drugs.
    • Accurate reporting of adverse effects in drug labels is crucial for patient safety.
    • Previous assessments of statin adverse effect reporting have yielded varied conclusions.

    Purpose of the Study:

    • To systematically evaluate the accuracy of adverse effects listed in statin product labels.
    • To compare label-reported adverse effects with findings from meta-analyses of randomized controlled trials (RCTs).

    Main Methods:

    • A meta-analysis of double-blind, randomized controlled trials (RCTs) of statin therapy was conducted.
    • Adverse effects reported in product labels were systematically identified.
    • The frequency and nature of label-reported adverse effects were compared against pooled data from RCTs.

    Main Results:

    • The meta-analysis found that adverse effects attributed to statin therapy in product labels were generally consistent with findings from RCTs.
    • Specific adverse events, such as muscle-related symptoms, were appropriately reflected in labeling.
    • Minor discrepancies in the reporting of less common adverse events were observed but did not significantly alter the overall safety profile.

    Conclusions:

    • Statin product labels provide a largely accurate representation of known adverse effects based on robust clinical trial evidence.
    • The findings support the reliability of regulatory labeling for informing clinical practice and patient decision-making regarding statin use.
    • Continued pharmacovigilance and periodic review of drug labels are recommended.